4.7 Review

Interplay between SOX9 transcription factor and microRNAs in cancer

Journal

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 183, Issue -, Pages 681-694

Publisher

ELSEVIER
DOI: 10.1016/j.ijbiomac.2021.04.185

Keywords

SOX9; Transcription factor; MicroRNA; Cancer; Long non-coding RNA; Circular RNA

Funding

  1. Ministry of Education - Singapore [MOE-T2EP30120-0016]
  2. National Research Foundation Singapore
  3. Ministry of Education - Singapore under its Research Center of Excellence initiative to Cancer Science Institute of Singapore
  4. National University of Singapore
  5. US NIH [R01AI050875, R21AI121700]

Ask authors/readers for more resources

SOX9, a critical transcription factor in the SOXE family, regulates the expression of different transcription factors in cancer cells by binding to miRNAs, affecting cancer progression and malignancy. Other non-coding RNAs can also regulate the expression of miRNA/SOX9 to promote/inhibit cancer progression.
SOX transcription factors are critical regulators of development, homeostasis and disease progression and their dysregulation is a common finding in various cancers. SOX9 belongs to SOXE family located on chromosome 17. MicroRNAs (miRNAs) possess the capacity of regulating different transcription factors in cancer cells by binding to 3'-UFR. Since miRNAs can affect differentiation, migration, proliferation and other physiological mechanisms, disturbances in their expression have been associated with cancer development. In this review, we evaluate the relationship between miRNAs and SOX9 in different cancers to reveal how this interaction can affect proliferation, metastasis and therapy response of cancer cells. The tumor-suppressor miRNAs can decrease the expression of SOX9 by binding to the 3'-UTR of lnRNAs. Furthermore, the expression of downstream targets of SOX9, such as c-Myc, Wnt, PI3K/Akt can be affected by miRNAs. It is noteworthy that other non-coding RNAs including lncRNAs and circRNAs regulate miRNA/SOX9 expression to promote/inhibit cancer progression and malignancy. The pre-clinical findings can be applied as biomarkers for diagnosis and prognosis of cancer patients. (C) 2021 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available